Literature DB >> 22877922

Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study.

Chi-Shin Wu1, Sheng-Chang Wang, Susan Shur-Fen Gau, Hui-Ju Tsai, Yu-Cheng Cheng.   

Abstract

BACKGROUND: Previous research suggests a link between antipsychotic use and stroke, but the relationships between receptor-binding profiles of antipsychotics and the risk of cerebrovascular events are unclear.
METHODS: A total of 14,584 patients with incident stroke were enrolled in the National Health Insurance Research Database in Taiwan from 1998 to 2007. We conducted a case-crossover study to compare the rates of antipsychotic use. The effects of receptor-binding profiles of antipsychotics on stroke risk were estimated, while the moderating effects of age, sex, presence of dementia, and duration of antipsychotic treatment were evaluated by stratified analyses.
RESULTS: The adjusted odds ratio of stroke risk with antipsychotics exposure was 1.60 (95% confidence interval, 1.51-1.69) using a 14-day time window. The use of antipsychotics with a high binding affinity of M1 muscarinic and α2 adrenergic receptors was associated with a greater risk of stroke than the use of other types of antipsychotics. An increased risk of stroke with antipsychotic use was noted in the patients who were older and/or who suffered from dementia. Moreover, our results showed that stroke risk with antipsychotic use was in a dose-related relationship.
CONCLUSIONS: Our findings suggest an association between stroke risk and high M1 muscarinic and α2 adrenergic affinity. The clinical implication is to start antipsychotics treatment at low dosages and to closely monitor the side effects in the initial treatment, particularly for individuals with older age and the presence of dementia.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22877922     DOI: 10.1016/j.biopsych.2012.07.006

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Association of quetiapine with ischemic brain stem stroke: a case report and discussion.

Authors:  Selma BozkurtZincir; Betul F Ozdilek; Serkan Zincir
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 2.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs.

Authors:  John W Jackson; Tyler J VanderWeele; Anand Viswanathan; Deborah Blacker; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2014-09-18       Impact factor: 4.897

Review 4.  Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.

Authors:  Marta Miarons; Christopher Cabib; Francisco Javier Barón; Laia Rofes
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

5.  Association between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohort.

Authors:  Shao-Yuan Chuang; Pai-Feng Hsu; Fang-Ju Lin; Ya-Wen Huang; Gou-Zhau Wang; Wei-Chiao Chang; Hui-Ju Tsai
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

6.  Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.

Authors:  Christoph U Correll; Benjamin I Joffe; Lisa M Rosen; Timothy B Sullivan; Russell T Joffe
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

7.  Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia.

Authors:  Monika Marcinkowska; Adam Bucki; Joanna Sniecikowska; Agnieszka Zagórska; Nikola Fajkis-Zajączkowska; Agata Siwek; Monika Gluch-Lutwin; Paweł Żmudzki; Magdalena Jastrzebska-Wiesek; Anna Partyka; Anna Wesołowska; Michał Abram; Katarzyna Przejczowska-Pomierny; Agnieszka Cios; Elżbieta Wyska; Kamil Mika; Magdalena Kotańska; Paweł Mierzejewski; Marcin Kolaczkowski
Journal:  J Med Chem       Date:  2021-08-26       Impact factor: 7.446

8.  Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia.

Authors:  Ahsan Rao; Amna Suliman; Giles Story; Sabine Vuik; Paul Aylin; Ara Darzi
Journal:  Int J Methods Psychiatr Res       Date:  2016-04-27       Impact factor: 4.035

9.  Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2016-04-12       Impact factor: 3.199

10.  Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke.

Authors:  Mu-En Liu; Shih-Jen Tsai; Wei-Chiao Chang; Chun-Hung Hsu; Ti Lu; Kuo-Sheng Hung; Wen-Ta Chiu; Wei-Pin Chang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.